Клексан

Quick links to important sections

Клексан

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Клексан

What is Клексан? Factual Overview and Classification

Property Description
Active ingredient Enoxaparin Sodium
Form Solution for Injection (prefilled syringes)
Pharmacological class Anticoagulant, Low Molecular Weight Heparin (LMWH)
Common use Preventing blood clots (antithrombotic)
Origin Biosynthetic (Heparin derivative)

What Type of Medicine is Клексан?

Клексан (Clexane) is a specialized Anticoagulant medication and an Antithrombotic agent, whose primary function is to reduce the risk of abnormal blood clot formation. It is formally classified as a Low Molecular Weight Heparin (LMWH), a designation that distinguishes it chemically and functionally from standard, Unfractionated Heparin (UFH). The general therapeutic purpose of this product is to intervene in the complex coagulation process, thereby maintaining blood flow in individuals where the risk of clotting is elevated. LMWHs are clinically recognized agents for the prevention and management of thromboembolic disorders.

Enoxaparin Sodium: Composition and Origin

The single active ingredient in this medicinal product is Enoxaparin Sodium, which is derived from porcine intestinal mucosa and obtained through a controlled chemical depolymerization. This process generates a smaller, more uniform molecule, establishing its biosynthetic identity as a polysaccharide compound. The medication is presented as a sterile, aqueous solution for injection, typically supplied in prefilled syringes, requiring parenteral administration because its molecular properties prevent effective absorption if taken orally.

How Does Клексан Achieve its General Purpose?

The mechanism by which Клексан achieves its general purpose is by specifically disrupting the activity of a critical coagulation protein known as Factor Xa. The medication selectively binds to an enzyme in the bloodstream that, in turn, inactivates Factor Xa, effectively slowing the initial stages of the clotting cascade. This precise function is key to its role as a predictable anticoagulant, or 'blood thinner,' which helps prevent the development of unwanted or excessive clot structures that could otherwise obstruct normal circulation.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Клексан?

Possible Side Effects and Safety Information

The safety profile of Клексан (Enoxaparin), classified as a Low Molecular Weight Heparin (LMWH), is primarily defined by the risk of hemorrhage (bleeding) inherent to its role as an anticoagulant. This profile is organized in regulatory documents by frequency and affected body systems.


Officially Documented Adverse Reactions

Adverse reactions are formally categorized based on incidence rates observed in clinical studies:

  • Very Common: Bleeding events (hemorrhage) are frequently documented in some patient populations and indications.
  • Common: Other common effects include general hemorrhage, thrombocytopenia (low platelet count), elevated liver enzymes (serum aminotransferases), anemia, and reactions at the injection site such as pain or bruising (hematoma).
  • Rare: Rare but serious reactions documented in official labeling include Heparin-Induced Thrombocytopenia (HIT) with thrombosis, intracranial hemorrhage, and Spinal or Epidural Hematoma.

Serious Safety Considerations

The most serious documented safety concerns include Major Hemorrhage and the formation of a Spinal or Epidural Hematoma, particularly when the medicine is used concurrently with procedures like spinal or epidural anesthesia. Furthermore, HIT is a specific, rare, immune-mediated complication of the heparin class.

Population-Specific Notes

The official label includes specific considerations for certain patient groups. For individuals with severe renal impairment (creatinine clearance less than 30 mL/ min), dosage adjustment is necessary due to the drug's elimination route. Older adults are officially noted to have an increased risk of bleeding events. The multiple-dose formulation contains benzyl alcohol, a preservative associated with risks in neonates and infants.

Overdose and Emergency Response

Accidental overdosage with Клексан (enoxaparin sodium) may cause hemorrhage, which is the primary documented manifestation resulting from an exaggerated anticoagulant effect. Documented clinical presentations of overdosage include excessive bleeding, unusual bruising, blood in urine or stools, and vomit resembling coffee grounds. Severe outcomes are associated with significant bleeding, including the risk of intracranial hemorrhage or spinal/epidural hematomas. These complications may be signaled by sudden severe headache, weakness, or loss of motor control, requiring urgent medical action. Regulators mandate that patients seek emergency medical attention or call the Poison Help line immediately if overdosage is suspected. Contact with emergency services is required if the individual has collapsed, had a seizure, or is experiencing trouble breathing.

The official labeling specifies protamine sulfate solution as the designated neutralizing agent, given via gradual intravenous injection. This agent is noted to provide only partial neutralization of the drug's anti-Factor Xa activity, and specific caution is required to avoid protamine overdose. A regulatory note highlights that patients with severe renal impairment face an increased risk of drug accumulation, which elevates the potential for overdosage.

Therapeutic Uses of Клексан

What Клексан Treats: Main Uses and Benefits

Клексан (Enoxaparin sodium) is an anticoagulant medication belonging to the class of low molecular weight heparins (LMWH). Its primary function is to prevent and treat various types of blood clots, which are essential for maintaining healthy blood flow and preventing serious cardiovascular complications.

Prevention of Venous Thromboembolism (VTE)

One of the primary uses of Клексан is the prevention of venous thromboembolism, which includes conditions such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This is particularly important in several clinical scenarios:

  • Surgical Procedures: Patients undergoing orthopedic surgery (such as hip or knee replacements) or general surgery are at a higher risk of developing blood clots due to prolonged immobility and the body’s natural response to surgery. Клексан helps reduce this risk during the recovery period.
  • Medical Immobilization: Individuals who are hospitalized with acute medical illnesses—such as heart failure, respiratory failure, or severe infections—and are unable to move freely may receive Клексан to prevent clot formation.

Treatment of Existing Blood Clots

Beyond prevention, Клексан is used to treat active cases of deep vein thrombosis and pulmonary embolism. By preventing the existing clot from growing larger, the medication allows the body’s natural mechanisms to gradually dissolve the clot, thereby reducing the risk of long-term complications or life-threatening events.

Management of Acute Coronary Syndromes (ACS)

Клексан plays a significant role in managing certain types of heart-related conditions where blood flow to the heart muscle is compromised. These include:

  • Unstable Angina: Used to prevent a complete blockage of the coronary arteries.
  • Myocardial Infarction (Heart Attack): Клексан is often administered alongside other treatments to manage specific types of heart attacks, helping to restore and maintain blood flow to the cardiac tissue.

Prevention of Extracorporeal Coagulation

During hemodialysis, blood is circulated through a machine outside the body. To prevent the blood from clotting within the dialysis equipment, Клексан may be used to ensure the procedure remains effective and safe for the patient.

Benefits of Therapy

The use of Клексан offers several clinical benefits centered on vascular health:

  • Predictable Anticoagulant Effect: Compared to standard unfractionated heparin, low molecular weight heparins like Клексан offer a more consistent and predictable response.
  • Reduced Risk of Complications: By effectively preventing and treating clots, the medication helps avoid secondary complications such as post-thrombotic syndrome or sudden pulmonary blockages.
  • Convenience of Use: Its pharmacological profile often allows for standardized applications that support both hospital-based and outpatient care transitions.

Eligibility and Restrictions for Use

Who can and cannot use Клексан? Official Regulatory Information

Official regulatory documents define strict criteria for patient eligibility for Клексан (Enoxaparin Sodium).


Populations and Conditions Prohibited from Use (Contraindicated)

Use of this medicine is absolutely contraindicated in patients experiencing active major bleeding or those with a documented history of Immune-Mediated Heparin-Induced Thrombocytopenia (HIT). It is also prohibited for individuals with a known hypersensitivity to enoxaparin, heparin, or pork products. Furthermore, the multi-dose formulation containing benzyl alcohol must not be administered to newborns or premature neonates.


Restricted and Conditional Use

Eligibility is conditional for certain groups, requiring special consideration as documented in the label:

  • Severe Renal Impairment (CrCl < 30 mL/min): Use is restricted and requires specific dose adjustment or is generally not recommended by some authorities.
  • Geriatric Patients (75+ years): Use is permitted but requires close monitoring due to an increased risk of bleeding.
  • Pediatric Population: Safety and efficacy are not established for most indications in children.
  • Pregnancy and Lactation: Use is generally permitted, but pregnant women with mechanical prosthetic heart valves are at an increased risk of thrombosis and require strict monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for enoxaparin sodium is structured around pharmacodynamic risk reinforcement and pharmacokinetic elimination dependency. It is not associated with CYP450 enzyme or small-molecule transporter-mediated drug-drug interactions.


Documented Pharmacodynamic Interactions

The most significant documented interaction involves co-administration with agents that affect the body's clotting system. This pharmacodynamic effect leads to an enhanced risk of hemorrhage.

  • Medicines in this category include antiplatelet agents (e.g., aspirin), non-steroidal anti-inflammatory drugs (NSAIDs), other anticoagulants (e.g., warfarin), and thrombolytic agents.
  • The use of alcohol is also documented as potentially increasing the overall risk of bleeding.

Procedural and Timing Constraints

Specific restrictions are mandated for patients undergoing Neuraxial Anesthesia (e.g., spinal or epidural anesthesia) or Spinal Puncture. Official prescribing information requires a specific time interval between the last dose of enoxaparin and the procedure (or catheter removal) to mitigate the labeled risk of spinal or epidural hematoma.

Pharmacokinetic and Population-Specific Notes

Enoxaparin elimination depends heavily on renal function. For patients with Severe Renal Impairment (Creatinine Clearance < 30 mL/min), official data shows significantly increased anti-Factor Xa exposure (AUC) due to decreased drug clearance. This requires careful monitoring.

Mechanism of Action

How Клексан Works: Mechanism of Action

The pharmacological effect of Клексан (Enoxaparin Sodium) is defined by its enzyme-mediated intervention in the body’s coagulation system.


Specific Catalytic Inhibition of Factor Xa

The primary mechanism involves Клексан binding to the natural plasma protein Antithrombin (ATIII), acting as a catalyst to greatly increases ATIII's inhibitory rate. This augmented activity is specifically directed at Coagulation Factor Xa (FXa), an essential enzyme in the blood clotting cascade. By forming a stable complex with FXa, the drug rapidly and selectively inactivates this essential enzyme, thereby modulating a key molecular step required for clot formation.


Intervention in the Thrombin Generation Pathway

By blocking the activity of FXa, the drug interrupts the final common pathway of coagulation. Since FXa is required to generate Thrombin (FIIa), this inactivation significantly impairs the overall production of this downstream enzyme. Thrombin is responsible for converting fibrinogen into the stable fibrin mesh. The physiological consequence of this interference is the attenuation of the blood's capacity to build and strengthen new clot structures, producing a reduced capacity for coagulation.


Mechanistic Selectivity and Constraints

The molecule's structure defines its mechanistic profile; as a Low Molecular Weight Heparin (LMWH), its chain is too short to effectively perform the "bridging" necessary to simultaneously inhibit both ATIII and Thrombin (FIIa). Consequently, the mechanism exhibits a pronounced and selective anti-FXa effect while possessing only a minimal anti-FIIa effect. This specificity dictates that its mechanism is primarily centered on inhibiting clot formation and propagation, having negligible direct activity on dissolving established clots.

Dosage and Administration Information

How to use Клексан

Клексан (enoxaparin sodium) administration adheres to official, standardized protocols that define the precise route, dosing, and patient-specific adjustments. The medicine is administered primarily via subcutaneous (SC) injection for both the prevention and treatment of clotting events. An intravenous (IV) bolus is a specific exception, used exclusively to initiate treatment for acute ST-segment Elevation Myocardial Infarction (STEMI).

Dosing schedules vary based on purpose and patient weight. Prophylaxis (prevention) regimens involve fixed doses, such as 40 mg SC once daily or 30 mg SC every 12 hours. Treatment regimens typically use weight-based calculations, such as 1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily. Treatment courses continue for a minimum of five days and are maintained until a concurrent oral anticoagulant reaches its therapeutic target.

Procedural constraints dictate that the SC injection site must be alternated along the anterolateral or posterolateral abdominal wall. For 20 mg and 40 mg prefilled syringes, the air bubble must not be expelled prior to the SC injection. Post-operative dosing is generally initiated 12 to 24 hours after surgery once hemostasis is confirmed.

Mandatory dose adjustment is required for patients with severe renal impairment (CrCl < 30 mL/min), which typically reduces the treatment frequency to once daily. Similarly, older adults (75 years) receiving STEMI treatment require a modified dose; the initial IV bolus is omitted, and the SC dose is reduced to 0.75 mg/kg every 12 hours. The medicine must not be administered via the intramuscular route.

Recent Clinical Evidence

Клексан (Enoxaparin): Overview of Clinical Evidence

Clinical trials and established guidelines confirm the role of enoxaparin, the active ingredient in Клексан, across several indications primarily related to thromboembolism. Enoxaparin is a low molecular weight heparin (LMWH) commonly used for the prevention and treatment of blood clots.


Prevention of Venous Thromboembolism (VTE)

Extensive clinical data supports the use of enoxaparin for VTE prophylaxis in various patient populations:

  • Surgical Patients: Studies, including randomized controlled trials, consistently show a reduction in the incidence of deep vein thrombosis (DVT) in patients undergoing high-risk procedures, such as hip or knee replacement surgery, and general abdominal surgery.
  • Medically Ill Patients: Research has shown that prophylaxis with enoxaparin is associated with a lower risk of VTE compared to placebo in acutely ill medical patients who have severely restricted mobility.

Management of Acute Coronary Syndromes (ACS)

Enoxaparin has been investigated as an anticoagulant in conjunction with antiplatelet therapy (e.g., aspirin) for patients experiencing acute coronary syndromes, including Unstable Angina (UA) and Non-ST-Elevation Myocardial Infarction (NSTEMI). Comparative studies have evaluated its utility against unfractionated heparin (UFH) in these settings, with findings supporting its role in reducing complications.

  • ST-Elevation Myocardial Infarction (STEMI): Enoxaparin is also used in the management of acute STEMI, often in combination with a thrombolytic agent or as part of a percutaneous coronary intervention (PCI) strategy.

Treatment of Established Clots

For the treatment of acute DVT, with or without an associated pulmonary embolism (PE), clinical evidence supports the use of enoxaparin, often initiated with the aim of preventing clot extension or recurrence. In these cases, treatment is typically continued until a transition to oral anticoagulant therapy is safely achieved.

Research continues to explore dosing strategies in specific populations, such as those with severe kidney impairment or low body weight, to optimize the balance between preventing thrombosis and minimizing the risk of bleeding events.

Key Studies & References

  1. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NICE Guideline NG89)
  2. Enoxaparin - StatPearls (Source for clinical conditions and general use)

Frequently Asked Questions (FAQ)

Common questions about Клексан (FAQ)


Q: How quickly does Клексан start working after the first use?

The process of anti-clotting activity begins rapidly after injection. According to regulatory documents, the maximum level of the anti-clotting substance in the blood, known as anti-Factor Xa activity, is reached approximately 3 to 5 hours after a subcutaneous injection. This shows the medicine begins working within a few hours to modulate the coagulation process.

Q: How long does the effect of a Клексан dose last?

The effect of the drug lasts for several hours. The half-life, which is the time it takes for half of the anti-clotting activity to leave the bloodstream, is about 4 hours after a single dose and can be around 7 hours after multiple daily doses. This half-life supports the administration frequency described in the prescribing information.

Q: Is it normal to feel a burning or stinging sensation after the injection?

Yes, regulatory documentation states that some people may experience local reactions at the injection site. This includes irritation, pain, or burning sensations, in addition to common effects like bruising. This is a recognized side effect associated with the injection process.

Q: Can vitamins or herbal supplements interact with Клексан?

Official sources advise caution regarding certain herbal supplements. Specifically, those known to have potential blood-thinning properties, such as ginkgo biloba or garlic, may increase the overall risk of bleeding. The potential interaction of supplements is a subject for discussion with a healthcare provider.

Q: How does Клексан compare to Warfarin (Coumadin) in terms of general use?

Клексан is an injectable medication often used for initial, short-term treatment or prevention of blood clots. Warfarin is an oral anticoagulant typically used for long-term therapy. Official protocol states that the injectable medication is often continued for a short period until the patient's blood test results (INR) show they have reached a therapeutic level on the oral medicine.

Q: Why do some people need to inject Клексан for a long time?

The duration of treatment is based on the specific condition and the risk of clotting. For certain high-risk situations, such as prophylaxis after hip replacement surgery, extended use of up to three weeks may be prescribed. Longer-term use is also often required for the management of cancer-related blood clots.

Q: Can a person stop using Клексан suddenly?

Regulatory information indicates that the duration of treatment is precisely defined by the underlying medical condition and risk factors. Cessation typically occurs when a therapeutic oral anticoagulant effect has been achieved or when the risk of clot formation has diminished. Adherence to the full prescribed course is described as important for managing the patient's underlying condition.

Q: What if I forget to use my dose of Клексан?

Official guidance advises that if a dose is missed, it should be administered as soon as it is remembered, provided it is still the same day. This timing is intended to help maintain the level of the medicine in the bloodstream. If the entire day is missed, a healthcare provider should be consulted for specific instructions.

Q: What are the signs of an allergic reaction to Клексан?

Official warnings note that signs of a serious allergic reaction may include hives, itching or burning skin, or dizziness. More severe symptoms can involve difficulty breathing and swelling of the face, lips, tongue, or throat. The onset of these symptoms is an important signal to seek emergency care.

Q: Does Клексан contain latex or other common allergens?

Regulatory information confirms the drug is contraindicated for those allergic to the active ingredient, enoxaparin, as well as heparin or pork products. The multi-dose formulation also contains the preservative benzyl alcohol. Patients typically consult their pharmacist or healthcare team regarding the full list of components in their specific product formulation.

Q: What common foods or drinks are known to affect Клексан?

Aside from alcohol, which can increase the overall risk of bleeding, specific common foods are not routinely listed as affecting the drug. However, the official label advises that certain herbal supplements that have blood-thinning properties may increase the risk of bleeding.

Q: Does Клексан cause fatigue or tiredness?

While fatigue itself is not consistently listed as a direct side effect, official documents cite anemia (low red blood cells) as a common adverse reaction. Anemia is a condition that can lead to symptoms such as unusual tiredness or feeling light-headed.

Q: Can Клексан be used by people with a history of stomach ulcers?

A history of a stomach ulcer or other gastrointestinal bleeding is considered a risk factor because the drug increases the risk of hemorrhage. This condition is described in the label as requiring a healthcare provider's review and is an important consideration before starting the medicine.

Q: Is there a test to check if Клексан is working correctly (non-personalized)?

Yes, for certain patient populations (e.g., those with severe kidney impairment or body weight extremes), the anti-clotting effect may be monitored. This is done by measuring Anti-Factor Xa concentrations in the blood to ensure the drug level is within the appropriate range.

Q: What does the term 'low molecular weight heparin' mean?

Low Molecular Weight Heparin (LMWH) is derived from standard heparin that has been processed into shorter chains and fragments. This chemical difference is important because it makes the drug's activity more predictable in the body, which enables convenient dosing.

Q: Is it possible to overdose on Клексан?

Yes, an overdose is possible. If an overdose is suspected, a specific substance, protamine sulfate, may be used to counteract the effects of the drug.

Q: Do people gain weight while using Клексан?

Weight gain is not explicitly listed as a side effect. However, fluid retention (edema) or swelling of the ankles, hands, or feet is listed in the official documents as a common adverse reaction, which may be mistaken for weight gain.

Q: Why is it important to rotate the injection sites when using Клексан?

According to administration guidelines, injection site rotation is necessary to minimize bruising and to prevent skin problems such as the skin hardening at the injection site. Alternating sites is a necessary part of the standard usage protocol.

Q: Are there different brands of Enoxaparin, and what are the main differences?

Yes, Enoxaparin Sodium is the active ingredient and is sold under different brand names and as a generic product. Regulatory agencies require that generic versions have the same active ingredient as the brand-name product to ensure equivalent quality and performance.

Q: Does Клексан have any known effects on mental clarity or mood?

Confusion is listed as a potential common side effect of Enoxaparin in official documents. This means that an effect on mental clarity or cognitive function has been documented.

Q: Is it possible to take Клексан if I have an upcoming minor procedure or dental work?

The label emphasizes caution and requires specific time intervals around procedures that carry a risk of bleeding. Regulatory warnings indicate that the timing of any procedure, including minor or dental work, should be discussed with a healthcare provider before the medication is used.

Q: Are there any long-term effects associated with using Клексан?

For long-term use, official safety information notes a potential concern regarding loss of bone strength (osteoporosis). This risk is primarily associated with the general class of heparin drugs, and patients on extended treatment are monitored for this.

Q: What should be done if I notice unusual bleeding while on Клексан?

Patients are instructed in official materials to seek immediate medical help if symptoms of severe bleeding are experienced. These symptoms include black or bloody stools, blood in urine, or vomiting blood.

Q: Can Клексан be used by people who have diabetes?

Use is not contraindicated, but official warnings advise that patients with eye problems caused by diabetes should inform their doctor, as this condition may increase the risk of bleeding complications.

Q: Why is it necessary to inject Клексан at a specific time each day?

Consistent injection timing (e.g., 'at the same time every day' or 'every 12 hours') is an important administration instruction. This is necessary to maintain a predictable and stable level of the anti-clotting effect in the bloodstream throughout the day, which supports its intended safety and efficacy.


How should Клексан be stored and disposed of?

How to Store and Dispose of Clexane (Enoxaparin Sodium)

Official Storage Requirements

Clexane must be stored at controlled room temperature, typically below 25°C (77°F), and must not be frozen. The prefilled syringes should be kept in the original carton until the time of use to maintain integrity and must be stored out of the sight and reach of children.

Disposal Instructions

Used Clexane prefilled syringes are classified as sharps. They must be placed immediately into an FDA-cleared sharps disposal container after injection. Unused or expired medication should not be disposed of in household trash or wastewater; consult local pharmaceutical waste guidelines for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Клексан found in:

A-Z Index: